Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma | Zendy

Parameswaran Nair | Zendy; Sally E. Wenzel | Zendy; Klaus F. Rabe | Zendy; Arnaud Bourdin | Zendy; Njira Lugogo | Zendy; Piotr Kuna | Zendy; Peter Barker | Zendy; Stephanie Sproule | Zendy; Sandhia Ponnarambil | Zendy; Mitchell Goldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

Author(s) -

Parameswaran Nair,

Sally E. Wenzel,

Klaus F. Rabe,

Arnaud Bourdin,

Njira Lugogo,

Piotr Kuna,

Peter Barker,

Stephanie Sproule,

Sandhia Ponnarambil,

Mitchell Goldman

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1703501

Subject(s) - benralizumab , medicine , placebo , asthma , glucocorticoid , exacerbation , randomization , adverse effect , randomized controlled trial , gastroenterology , eosinophil , mepolizumab , pathology , alternative medicine

Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research